Post-marketing safety surveillance and reevaluation of Motherwort injection: A clinical study of 10 094 cases

Shan Cao, Wenhao Zhang, Zhao Ziwei, Heng Mingli, Huaien Bu, Hongwu Wang, Xinghui Liu, Zhong Wang, Yan Cai, Yuyan Ma, Cui Shihong, Deng Jihong, Guifeng Ding, Ding Yajuan, Dong Linhong, Duan Zhentao, Fan Ling, Fan Yang, F Fu, He Jing, Ji Shuying, Jin Lin, Hong Li, Tao Liao, Wei Lu, Xiucui Luo, Lv Zhihui, Ma Fengchun, Ma Dafeng, Tianyun Shi, Sun Juying, Xiaotong Sun, Teng Hong, Wang Jinhua, Ruihua Wang, Ying Wang, Zhengling Wang, Jie Xi, Xu Min-juan, Zhihong Xu, Yan Qian, Yang Cuirong, Yang Yimei, Jie Yin, Yu Jin-hua, Yuan Wen-jun, Guanli Zhang, Zhang Meihua, Zhao Renfeng, Zhong Yonghong, Jian ZhouJournal of Traditional Chinese Medicine 2018 · DOI

Abstract

To investigate the safety profiles of Motherwort injection (MI). A multi-center, prospective and drug-derived hospital intensive monitoring method was conducted to assess the safety of MI in real world applications. This study was based on a very large population after the injection was approved and marketed in China. All patients using the injection in participating hospitals were monitored to determine the incidence, pattern, severity and outcome of associated adverse events. The post-marketing surveillance was performed in 10 094 female patients from April to December, 2015. The incidence of adverse drug reactions (ADRs) was 0.79‰ (8/10 094). Among the 8 patients, the reported adverse events mainly included systemic abnormalities, such as fever, chills and eyelid edema; skin and appendages disorders, such as pruritus and rash; gastrointestinal disorders, such as nausea, abdominal distension and pain; heart rate and rhythm disorders, such as palpitation and increased heart rate. All of these ADRs were mild in severity. In this study the ADRs incidence rate of MI is very low, which supports that it is generally safe for use in obstetric and gynecological diseases. However, the total number of 8 ADRs recorded over a relatively short time span seems limited, and the low number of reports could not represent an absolute guarantee of safety.
BibTeX
@article{cao2018post,
  author = {Shan Cao and Wenhao Zhang and Zhao Ziwei and Heng Mingli and Huaien Bu and Hongwu Wang and Xinghui Liu and Zhong Wang and Yan Cai and Yuyan Ma and Cui Shihong and Deng Jihong and Guifeng Ding and Ding Yajuan and Dong Linhong and Duan Zhentao and Fan Ling and Fan Yang and F Fu and He Jing and Ji Shuying and Jin Lin and Hong Li and Hongying Li and Tao Liao and Wei Lu and Xiucui Luo and Lv Zhihui and Ma Fengchun and Ma Dafeng and Tianyun Shi and Sun Juying and Xiaotong Sun and Teng Hong and Wang Jinhua and Ruihua Wang and Ying Wang and Zhengling Wang and Jie Xi and XU Min-juan and Zhihong Xu and Yan Qian and Yang Cuirong and Yang Yimei and Jie Yin and YU Jin-hua and Yuan Wen-jun and Guanli Zhang and Zhang Meihua and Zhao Renfeng and Zhong Yonghong and Jian Zhou},
  title = {{Post-marketing safety surveillance and reevaluation of Motherwort injection: A clinical study of 10 094 cases}},
  journal = {Journal of Traditional Chinese Medicine},
  year = {2018},
  doi = {10.1016/s0254-6272(18)30896-3},
}

Loading related content...

Figure